EFFICACY AND SAFETY OF ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES
Acetylsalicylic acid (ASA) use in the primary and secondary prevention of cardiovascular diseases is focused. Mode of ASA disaggregation action is discussed. Data of randomized controlled trials on ASA efficacy and safety in primary and secondary prevention are presented. The main groups of patients...
Saved in:
| Main Authors: | S. N. Tolpygina, S. Yu. Martsevich, E. N. Khoseva, N. V. Kiseleva |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-12-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/560 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current approaches to the selection of acetylsalicylic acid dosage forms in cardiology
by: S. R. Gilyarevskiy, et al.
Published: (2022-06-01) -
ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF STROKE
by: P. S. Laguta
Published: (2017-05-01) -
Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine?
by: O. V. Averkov
Published: (2010-04-01) -
Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025
by: Maciej Banach, et al.
Published: (2025-01-01) -
COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR)
by: S. Yu. Martsevich, et al.
Published: (2016-01-01)